Evidence map›Paper›PMID 27698689›Full record

ArticleExperimental and therapeutic medicine2016

Achievement of a target dose of bisoprolol may not be a preferred option for attenuating pressure overload-induced cardiac hypertrophy and fibrosis.

Shizhao Xiang, Ning Zhang, Zheng Yang, Zhouyan Bian, Yuan Yuan, Qizhu Tang

Open access · diamondAbstract read
In one paragraph

Article in Experimental and therapeutic medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 16 citations in OpenAlex.

  1. Exercise-induced βBrain, behavior, and immunity · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Shizhao XiangDepartment of Cardiology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China; Cardiovascular Research Institute of Wuhan University, Wuhan, Hubei 430060, P.R. China.
Ning ZhangDepartment of Cardiology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China; Cardiovascular Research Institute of Wuhan University, Wuhan, Hubei 430060, P.R. China.
Zheng YangDepartment of Cardiology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China; Cardiovascular Research Institute of Wuhan University, Wuhan, Hubei 430060, P.R. China.
Zhouyan BianDepartment of Cardiology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China; Cardiovascular Research Institute of Wuhan University, Wuhan, Hubei 430060, P.R. China.
Yuan YuanDepartment of Cardiology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China; Cardiovascular Research Institute of Wuhan University, Wuhan, Hubei 430060, P.R. China.
Qizhu TangDepartment of Cardiology, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China; Cardiovascular Research Institute of Wuhan University, Wuhan, Hubei 430060, P.R. China.
Renmin Hospital of Wuhan University · CNWuhan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bisoprolol is a drug that acts via the mechanism of specifically and selectively inhibiting the β

Indexed as

bisoprololcardiac fibrosiscardiac hypertrophyβ adrenoreceptor blocker

Identifiers

PMID27698689
PMCPMC5038470
OpenAlexW2478567788

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.